Raju Prasad
Stock Analyst at William Blair
(0.03)
# 3,309
Out of 4,479 analysts
12
Total ratings
16.67%
Success rate
-47.19%
Average return
Main Sectors:
Top Industries:
10 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DTIL Precision BioSciences | Downgrades: Market Perform | n/a | $9.41 | - | 1 | Jun 9, 2022 | |
| NTLA Intellia Therapeutics | Initiates: Outperform | n/a | $22.15 | - | 1 | Feb 18, 2022 | |
| LOGC ContextLogic | Downgrades: Market Perform | n/a | $5.67 | - | 1 | Feb 3, 2022 | |
| ASMB Assembly Biosciences | Downgrades: Market Perform | n/a | $13.35 | - | 1 | Sep 2, 2021 | |
| VERV Verve Therapeutics | Initiates: Outperform | n/a | $5.00 | - | 1 | Jul 12, 2021 | |
| TSHA Taysha Gene Therapies | Initiates: Outperform | n/a | $2.16 | - | 1 | Feb 24, 2021 | |
| GBIO Generation Bio Co. | Initiates: Outperform | n/a | $2.34 | - | 1 | Feb 24, 2021 | |
| CRSP CRISPR Therapeutics AG | Initiates: Market Perform | n/a | $53.12 | - | 1 | Mar 14, 2019 | |
| BOLD Boundless Bio | Downgrades: Market Perform | n/a | $4.30 | - | 2 | Nov 7, 2018 | |
| PTCT PTC Therapeutics | Upgrades: Outperform | n/a | $30.39 | - | 2 | Jun 18, 2018 |
Precision BioSciences
Jun 9, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $9.41
Upside: -
Intellia Therapeutics
Feb 18, 2022
Initiates: Outperform
Price Target: n/a
Current: $22.15
Upside: -
ContextLogic
Feb 3, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $5.67
Upside: -
Assembly Biosciences
Sep 2, 2021
Downgrades: Market Perform
Price Target: n/a
Current: $13.35
Upside: -
Verve Therapeutics
Jul 12, 2021
Initiates: Outperform
Price Target: n/a
Current: $5.00
Upside: -
Taysha Gene Therapies
Feb 24, 2021
Initiates: Outperform
Price Target: n/a
Current: $2.16
Upside: -
Generation Bio Co.
Feb 24, 2021
Initiates: Outperform
Price Target: n/a
Current: $2.34
Upside: -
CRISPR Therapeutics AG
Mar 14, 2019
Initiates: Market Perform
Price Target: n/a
Current: $53.12
Upside: -
Boundless Bio
Nov 7, 2018
Downgrades: Market Perform
Price Target: n/a
Current: $4.30
Upside: -
PTC Therapeutics
Jun 18, 2018
Upgrades: Outperform
Price Target: n/a
Current: $30.39
Upside: -